Safety of TG100-115 for Heart Attack Treated With Angioplasty
Status:
Completed
Trial end date:
2008-01-01
Target enrollment:
Participant gender:
Summary
TG100-115 is able to reduce the size of heart attacks in pre-clinical models. The hypothesis
of this study is that TG100-115 can be given safely to patients who suffer a heart attack and
undergo angioplasty to restore blood flow. We will also evaluate whether TG100-115 reduces
heart muscle damage.